ELGX
$3.01
Endologix
ELGX
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.73)
Revenue:  N/A
Wednesday
Feb 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, November 6, 2019

What do you expect when ELGX reports earnings?
Beat
Meet
Miss

Where is ELGX's stock price going from here?
Up
Flat
Down
Stock chart of ELGX
Analysts
Summary of analysts' recommendations for ELGX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.
Peers
StrykerBecton, DickinsonBoston ScientificBaxter InternationalAbbott LaboratoriesTeleflex3MWatersAbiomedIntegra LifeSciences Holdings